We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
-2.15%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$574M
AUM Growth
-$338M
Cap. Flow
-$522M
Cap. Flow %
-91.01%
Top 10 Hldgs %
44.83%
Holding
163
New
26
Increased
13
Reduced
41
Closed
50

Top Buys

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$12.3M
2
AMGN icon
Amgen
AMGN
+$11.3M
3
SLN
Silence Therapeutics
SLN
+$10.8M
4
VKTX icon
Viking Therapeutics
VKTX
+$9.06M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$6.59M

Top Sells

Rank Stock Value
1
CRBP icon
Corbus Pharmaceuticals
CRBP
+$10.5M
2
ALPN
Alpine Immune Sciences Inc
ALPN
+$10.4M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.14M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$7.96M
5
ANNX icon
Annexon
ANNX
+$5.3M

Sector Composition

Rank Sector Weight
1 Healthcare 55.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KPTI icon
101
Karyopharm Therapeutics
KPTI
$155M
$355K 0.06%
27,290
– –
ANVS icon
102
CALL
Annovis Bio
ANVS
$72.3M
$298K 0.05%
517
-249,483
-100% -$2.02M
LYRA
103
DELISTED
LYRA THERAPEUTICS INC
LYRA
$292K 0.05%
21,137
– –
AEON icon
104
AEON Biopharma
AEON
$10.7M
$271K 0.05%
3,583
– –
TPST icon
105
Tempest Therapeutics
TPST
$14.3M
$231K 0.04%
8,123
– –
CMMB
106
Chemomab Therapeutics
CMMB
$10.7M
$196K 0.03%
53,348
– –
JBIO
107
CALL
Jade Biosciences
JBIO
$1.18B
$166K 0.03%
+29
New +$19.2K
RLMD icon
108
Relmada Therapeutics
RLMD
$540M
$121K 0.02%
40,369
– –
STOK icon
109
Stoke Therapeutics
STOK
$1.84B
$92.1K 0.02%
6,816
– –
ABEO icon
110
CALL
Abeona Therapeutics
ABEO
$355M
$72.5K 0.01%
171
-67,329
-100% -$343K
SYBX
111
DELISTED
Synlogic
SYBX
$30.7K 0.01%
20,448
– –
BCLI
112
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$30.5K 0.01%
6,016
– –
CTMX icon
113
CytomX Therapeutics
CTMX
$690M
$10.9K ﹤0.01%
+8,924
New +$17.8K
ALNY icon
114
Alnylam Pharmaceuticals
ALNY
$38.3B
– –
-51,541
Closed -$8.14M
AMLX icon
115
CALL
Amylyx Pharmaceuticals
AMLX
$2.19B
– –
-1,060,100
Closed -$3.01M
AMLX icon
116
PUT
Amylyx Pharmaceuticals
AMLX
$2.19B
– –
-186,400
Closed -$529K
APLS
117
DELISTED
Apellis Pharmaceuticals
APLS
– –
-35,092
Closed -$2.06M
APLS
118
PUT
DELISTED
Apellis Pharmaceuticals
APLS
– –
-100,000
Closed -$5.88M
ATXS
119
CALL
DELISTED
Astria Therapeutics
ATXS
– –
-400,000
Closed -$5.63M
ATXS
120
DELISTED
Astria Therapeutics
ATXS
– –
-140,687
Closed -$1.98M
ATXS
121
PUT
DELISTED
Astria Therapeutics
ATXS
– –
-153,700
Closed -$2.16M
BHVN icon
122
CALL
Biohaven
BHVN
$2.02B
– –
-223,700
Closed -$12.2M
BMEA icon
123
CALL
Biomea Fusion
BMEA
$88.2M
– –
-1,077,600
Closed -$16.1M
BMEA icon
124
PUT
Biomea Fusion
BMEA
$88.2M
– –
-103,000
Closed -$1.54M
CABA icon
125
PUT
Cabaletta Bio
CABA
$427M
– –
-200,000
Closed -$3.41M
3 4
5
6 7

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Ikarian Capital held 163 positions worth $574M, down 37% from $912M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Ikarian Capital withdrew a net $522M in Q2 2024, closing 50 positions and reducing 41 holdings. Its most notable exit was Alpine Immune Sciences Inc, an estimated $10.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, up from 40% a quarter earlier.

Against the trend, Ikarian Capital opened a new position in Enliven Therapeutics worth $13.7M.

  • Ikarian Capital's largest Q2 2024 buy was Enliven Therapeutics: 586,552 shares worth $13.7M.
  • Ikarian Capital added most to Sarepta Therapeutics in Q2 2024, an estimated $6.59M increase.
  • Ikarian Capital's biggest Q2 2024 reduction was Corbus Pharmaceuticals, cutting an estimated $10.5M.
  • Ikarian Capital fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $10.4M.
  • Ikarian Capital's ten largest holdings make up 45% of its $574M portfolio in Q2 2024.
  • Ikarian Capital opened 26 new positions and closed 50 in Q2 2024.
  • Ikarian Capital's portfolio value fell 37% quarter-over-quarter to $574M.

Based on Ikarian Capital's 13F filing for Q2 2024, filed 14 Aug 2024.